source clinicalSource Clinical is an invaluable guide to the clinical research services sector, supporting pharmaceutical and biotechnology companies with the information they need to progress their drug candidates through the clinical development process.

Source Clinical comprises an extensive compilation of information on companies with the expertise to support and manage clinical research including suppliers of clinical trial quantities of drug products, contract test laboratories, operators of clinical research facilities and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

Through its comprehensive coverage, and with the support of One Nucleus and Bionow, Source Clinical is the reference tool supplying essential information that streamlines the clinical research partner selection process.

BioIVT acquires Ascendance Biotechnology

BioIVT logo 8.4.18BioIVT, a provider of biospecimens and related services, has acquired Ascendance Biotechnology, Inc. Ascendance was formed as a multinational cell-based assay company in November 2015 through the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. As a result of the acquisition, BioIVT has added Hepregen’s HepatoPac, HepatoMune and HepatoStem liver cell and stem cell product lines to its drug safety testing and toxicology portfolios.

Hepregen’s products employ a patented cell micropatterning technology in which different cell types are plated on industry-standard micro-well plates in proprietary patterns. The plates provide in-vitro cellular co-cultures that have a longer life and improved function. The HepatoPac products feature primary hepatocytes and fibroblasts that have been micro-patterned to create hepatocyte islands surrounded by supportive stromal cells. This approach closely mimics the function of a human liver and allows the hepatocytes to maintain normal metabolic activity for several weeks.

With HepatoMune, the micro-patterned primary hepatocytes and fibroblasts are supplemented with primary Kupffer cells, creating highly functional human liver tissue that models inflammation-mediated hepatotoxicity. HepatoMune tri-cultures remain viable for at least ten days, retaining both liver cell and Kupffer cell functionality, and can be used for predicting clinical outcomes. HepatoStem applies the same micro-patterning technology to stem cells.

For further information about BioIVT visit

Last modified onSunday, 08 April 2018 05:45